Pharmaceuticals, Biotechnology and Life Sciences
U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Hikma Pharmaceuticals’s US subsidiary West-Ward Pharmaceuticals has launched Ethacrynic Acid Tablets USP in 25mg strength, the generic equivalent to Edecrin (ethacrynic acid) for the treatment of edema when an agent with greater diuretic potential than those commonly employed is required.
The U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for Bayer’s copanlisib for the treatment of relapsed or refractory follicular lymphoma (FL) patients who have received at least two prior therapies.
A county in New York state has sued Purdue Pharma LP, Johnson & Johnson <JNJ.N> and other drugmakers, accusing them of engaging in fraudulent marketing that played down the risks of prescription opioid painkillers, leading to a drug epidemic.
Leigh Ann Pusey will join Eli Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly’s executive committee reporting directly to president and chief executive officer, David A. Ricks.
Healthcare conglomerate Johnson & Johnson <JNJ.N> said on Monday the U.S. Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.
Portola Pharmaceuticals has reported financial results for the quarter ended March 31, 2017.
Its have been three years since Ice bucket challenge went viral promoting awareness of amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease and encourage donations to research.
Tetraphase Pharmaceutical has reported a net loss of $29.5 million for the first quarter of 2017 which is decrease compared to a net loss of $16.7 million for the same period in 2016.
United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Pfizer’s Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) and XeljanzXR extended release 11 mg once daily use the treatment of adult patients with active psoriatic arthritis (PsA).